#1 Clinical Trials Search in Europe

177Lu-Dpi-4452

This article discusses the ongoing clinical trials of 177Lu-DPI-4452, a promising new drug being studied for the treatment of advanced or metastatic solid tumors. The trials aim to assess the safety, tolerability, and effectiveness of this innovative therapy in patients with specific types of cancer, including clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.

Table of Contents

What is 177Lu-DPI-4452?

177Lu-DPI-4452, also known as Debio 0228, is a new investigational drug being developed for the treatment of advanced solid tumors[1]. It is classified as a radiopharmaceutical, which means it combines a radioactive element (Lutetium-177) with a targeting molecule designed to seek out cancer cells[1].

Target Conditions

The clinical trial is focusing on patients with specific types of advanced or metastatic solid tumors that cannot be surgically removed. These include:

  • Clear cell renal cell carcinoma (ccRCC): A type of kidney cancer
  • Pancreatic ductal adenocarcinoma (PDAC): A common form of pancreatic cancer
  • Colorectal Cancer (CRC): Cancer that starts in the colon or rectum

These cancers are considered advanced when they have spread to other parts of the body or cannot be completely removed by surgery[1].

How 177Lu-DPI-4452 Works

177Lu-DPI-4452 is designed to target a specific protein called Carbonic Anhydrase IX (CA IX), which is often found in high levels on the surface of certain cancer cells[1]. The drug consists of two main parts:

  1. A targeting molecule that seeks out and attaches to CA IX on cancer cells
  2. A radioactive element (Lutetium-177) that delivers radiation directly to the cancer cells

This approach aims to deliver targeted radiation therapy to cancer cells while minimizing damage to healthy tissues[1].

Clinical Trial Overview

The clinical trial for 177Lu-DPI-4452 is a Phase 1/2 study divided into three parts[1]:

  • Part A: Evaluates the safety and imaging characteristics of a related compound, 68Ga-DPI-4452, which is used for diagnostic imaging.
  • Part B: Determines the appropriate dose of 177Lu-DPI-4452 for treatment.
  • Part C: Assesses the preliminary effectiveness of 177Lu-DPI-4452 in treating the targeted cancers.

The trial aims to understand how well the drug works, how safe it is, and how it moves through the body[1].

Potential Benefits

If successful, 177Lu-DPI-4452 could offer several potential benefits for patients with advanced solid tumors:

  • Targeted treatment that may be more effective than traditional therapies
  • Potentially fewer side effects compared to systemic chemotherapy
  • Ability to treat cancers that have not responded to other treatments
  • Possible improvement in survival rates and quality of life for patients with advanced cancers

Safety Considerations

As with any new treatment, safety is a primary concern. The clinical trial is carefully monitoring for side effects and adverse events. Some potential safety considerations include[1]:

  • Effects on bone marrow and blood cell counts
  • Impact on kidney and liver function
  • Potential for allergic reactions
  • Radiation-related side effects

Patients in the trial are closely monitored for any adverse effects, and the treatment can be adjusted or stopped if necessary[1].

Eligibility for Treatment

To be eligible for the clinical trial, patients must meet specific criteria, including[1]:

  • Having a confirmed diagnosis of one of the targeted cancer types
  • Having cancer that is advanced or has spread and cannot be surgically removed
  • Meeting specific health criteria, such as adequate organ function and blood cell counts
  • Not having certain medical conditions that could interfere with the treatment or increase risks

The exact eligibility criteria may vary depending on which part of the trial a patient is considering[1].

Future Prospects

177Lu-DPI-4452 represents a promising new approach in cancer treatment. If the clinical trials are successful, this therapy could potentially become an important option for patients with advanced solid tumors who have limited treatment options[1].

As research continues, more will be learned about the effectiveness and safety of this treatment. Patients interested in this therapy should discuss it with their oncologist to understand if it might be an appropriate option for their specific situation[1].

Aspect Details
Drug Name 177Lu-DPI-4452 (Debio 0228)
Study Type Phase 1/2, multicenter, open-label, non-randomized
Target Conditions Unresectable locally advanced or metastatic solid tumors (ccRCC, PDAC, CRC)
Primary Objectives Evaluate safety, tolerability, imaging characteristics, and efficacy
Administration Intravenous infusion
Key Measurements Adverse events, vital signs, ECG changes, pharmacokinetics, tumor response
Imaging Techniques PET/CT, SPECT/CT

FAQ

  • What is 177Lu-DPI-4452? 177Lu-DPI-4452 is an investigational drug being studied for the treatment of advanced or metastatic solid tumors. It is a radioactive medication that targets specific cancer cells.
  • What types of cancer are being studied with 177Lu-DPI-4452? The clinical trials are focusing on three types of advanced or metastatic solid tumors: clear cell renal cell carcinoma (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).
  • What is the main goal of the clinical trials? The main objectives of the trials are to evaluate the safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess the safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors.
  • How is the drug administered? 177Lu-DPI-4452 is administered intravenously (through a vein) as a solution for infusion.
  • What are some of the key things researchers are measuring in these trials? Researchers are measuring several factors, including the incidence and severity of side effects, changes in vital signs and ECG, how the drug is distributed in the body, its effectiveness in shrinking tumors, and how well it targets cancer cells compared to healthy tissue.

Ongoing Clinical Trials on 177Lu-Dpi-4452

  • Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Unresectable: Refers to a tumor that cannot be removed completely through surgery due to its size, location, or spread.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Clear cell renal cell carcinoma (ccRCC): A type of kidney cancer that begins in the lining of small tubes in the kidney.
  • Pancreatic ductal adenocarcinoma (PDAC): The most common type of pancreatic cancer, which starts in the ducts of the pancreas.
  • Colorectal Cancer (CRC): Cancer that starts in the colon or rectum, parts of the large intestine.
  • PET/CT: A combination of Positron Emission Tomography (PET) and Computed Tomography (CT) scans used to create detailed, 3D images of the body.
  • SPECT/CT: A combination of Single Photon Emission Computed Tomography (SPECT) and CT scans, used to produce 3D images showing how organs are functioning.
  • Radiopharmaceutical: A drug that contains a radioactive substance used for diagnosing or treating diseases.
  • Dosimetry: The measurement and calculation of radiation doses in the body.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-68gaga-dpi-4452-and-177lulu-dpi-4452-in-patients-with-advanced-or-metastatic-solid-tumors/